Self-Monitoring of Blood Glucose in Glucagon-Like Peptide-1–Based Treatment Approaches

Abstract

In Brief Recently, European expert recommendations suggested individualized self-monitoring of blood glucose (SMBG) strategies to optimize diabetes management in patients with type 2 diabetes who are treated with glucagon-like peptide-1 (GLP-1)-based approaches. These suggestions include simple and clinically applicable SMBG glucose testing patterns, or schemes. Potential benefits of SMBG in GLP-1-based treatment approaches were seen for several clinical scenarios: early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and diabetes education.

Development of a Patient Decision Aid on the Choice of Diabetes Medication for Filipino Patients with Type 2 Diabetes Mellitus

“…Information on daily sugar testing was based on one metaanalysis 43 and a consensus guideline from the International Diabetes Federation 44 except for liraglutide which was gathered from a European expert recommendation. 45 …”

Comparison of trajectories of self‐monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly

“…Self‐monitoring of blood glucose (SMBG) is considered a key component of disease management in patients with T2DM, particularly in those patients on treatment that is associated with hypoglycemic risk, namely insulin and sulfonylureas . Expert recommendations also suggest individualized SMBG measurement strategies to optimize diabetes management in patients with T2DM who are treated with GLP‐1RA . Most of the clinical studies and meta‐analyses have addressed the effects of structured and unstructured approaches to measure SMBG on overall glycemic control in patients treated with oral antidiabetic drugs (OADs) and insulin.…”

“…[15][16][17][18][19][20][21][22] Expert recommendations also suggest individualized SMBG measurement strategies to optimize diabetes management in patients with T2DM who are treated with GLP-1RA. [23][24][25] Most of the clinical studies and meta-analyses have addressed the effects of structured and unstructured approaches to measure SMBG on overall glycemic control in patients treated with oral antidiabetic drugs (OADs) and insulin. Only a few studies have evaluated the association between interor intraday glucose variability based on SMBG measures with the rate of hypoglycemia.…”